1.Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
Protein & Cell 2020;11(10):707-722
The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple organ failure. Despite advances in supportive care approaches, ARDS is still associated with high mortality and morbidity. Mesenchymal stem cell (MSC)-based therapy may be an potential alternative strategy for treating ARDS by targeting the various pathophysiological events of ARDS. By releasing a variety of paracrine factors and extracellular vesicles, MSC can exert anti-inflammatory, anti-apoptotic, anti-microbial, and pro-angiogenic effects, promote bacterial and alveolar fluid clearance, disrupt the pulmonary endothelial and epithelial cell damage, eventually avoiding the lung and distal organ injuries to rescue patients with ARDS. An increasing number of experimental animal studies and early clinical studies verify the safety and efficacy of MSC therapy in ARDS. Since low cell engraftment and survival in lung limit MSC therapeutic potentials, several strategies have been developed to enhance their engraftment in the lung and their intrinsic, therapeutic properties. Here, we provide a comprehensive review of the mechanisms and optimization of MSC therapy in ARDS and highlighted the potentials and possible barriers of MSC therapy for COVID-19 patients with ARDS.
Adoptive Transfer
;
Alveolar Epithelial Cells
;
pathology
;
Animals
;
Apoptosis
;
Betacoronavirus
;
Body Fluids
;
metabolism
;
CD4-Positive T-Lymphocytes
;
immunology
;
Clinical Trials as Topic
;
Coinfection
;
prevention & control
;
therapy
;
Coronavirus Infections
;
complications
;
immunology
;
Disease Models, Animal
;
Endothelial Cells
;
pathology
;
Extracorporeal Membrane Oxygenation
;
Genetic Therapy
;
methods
;
Genetic Vectors
;
administration & dosage
;
therapeutic use
;
Humans
;
Immunity, Innate
;
Inflammation Mediators
;
metabolism
;
Lung
;
pathology
;
physiopathology
;
Mesenchymal Stem Cell Transplantation
;
methods
;
Mesenchymal Stem Cells
;
physiology
;
Multiple Organ Failure
;
etiology
;
prevention & control
;
Pandemics
;
Pneumonia, Viral
;
complications
;
immunology
;
Respiratory Distress Syndrome, Adult
;
immunology
;
pathology
;
therapy
;
Translational Medical Research
2.Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.
Yelei GUO ; Kaichao FENG ; Yao WANG ; Weidong HAN
Protein & Cell 2018;9(6):516-526
Cancer stem cells (CSCs), a subpopulation of tumor cells, have self-renewal and multi-lineage differentiation abilities that play an important role in cancer initiation, maintenance, and metastasis. An accumulation of evidence indicates that CSCs can cause conventional therapy failure and cancer recurrence because of their treatment resistance and self-regeneration characteristics. Therefore, approaches that specifically and efficiently eliminate CSCs to achieve a durable clinical response are urgently needed. Currently, treatments with chimeric antigen receptor-modified T (CART) cells have shown successful clinical outcomes in patients with hematologic malignancies, and their safety and feasibility in solid tumors was confirmed. In this review, we will discuss in detail the possibility that CART cells inhibit CSCs by specifically targeting their cell surface markers, which will ultimately improve the clinical response for patients with various types of cancer. A number of viewpoints were summarized to promote the application of CSC-targeted CART cells in clinical cancer treatment. This review covers the key aspects of CSC-targeted CART cells against cancers in accordance with the premise of the model, from bench to bedside and back to bench.
Humans
;
Molecular Targeted Therapy
;
methods
;
Neoplasms
;
immunology
;
pathology
;
therapy
;
Neoplastic Stem Cells
;
pathology
;
Receptors, Chimeric Antigen
;
metabolism
;
T-Lymphocytes
;
immunology
;
metabolism
;
Translational Medical Research
3.Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study.
Chul Hyun CHO ; Yong Min AHN ; Se Joo KIM ; Tae Hyun HA ; Hong Jin JEON ; Boseok CHA ; Eunsoo MOON ; Dong Yeon PARK ; Ji Hyun BAEK ; Hee Ju KANG ; Vin RYU ; Hyonggin AN ; Heon Jeong LEE
Psychiatry Investigation 2017;14(1):100-106
The Mood Disorder Cohort Research Consortium (MDCRC) study is designed as a naturalistic observational prospective cohort study for early-onset mood disorders (major depressive disorders, bipolar disorders type 1 and 2) in South Korea. The study subjects consist of two populations: 1) patients with mood disorders under 25 years old and 2) patients with mood disorders within 2 years of treatment under 35 years old. After successful screening, the subjects are evaluated using baseline assessments and serial follow-up assessments at 3-month intervals. Between the follow-up assessments, subjects are dictated to check their own daily mood status before bedtime using the eMood chart application or a paper mood diary. At the regular visits every 3 months, inter-visit assessments are evaluated based on daily mood charts and interviews with patients. In addition to the daily mood chart, sleep quality, inter-visit major and minor mood episodes, stressful life events, and medical usage pattern with medical expenses are also assessed. Genomic DNA from blood is obtained for genomic analyses. From the MDCRC study, the clinical course, prognosis, and related factors of early-onset mood disorders can be clarified. The MDCRC is also able to facilitate translational research for mood disorders and provide a resource for the convergence study of mood disorders.
Bipolar Disorder
;
Cohort Studies*
;
Depressive Disorder
;
Depressive Disorder, Major
;
DNA
;
Follow-Up Studies
;
Humans
;
Korea
;
Mass Screening
;
Methods*
;
Mood Disorders*
;
Prognosis
;
Prospective Studies
;
Translational Medical Research
4.Application and development of patient-derived tumor xenograft model in translational medicine of tumor.
Zhenqiang WANG ; Zhenggang ZHU
Chinese Journal of Gastrointestinal Surgery 2017;20(5):596-600
Development of novel drugs is an integral part of the translational medicine in the field of cancer research, and the construction and application of preclinical animal models play vital roles in drugs development. Patient-derived tumor xenograft models (PDX) have been shown to be more accurate in prediction of clinical outcomes of novel drugs and are being used for preclinical drug evaluation based on the fact that PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor. To set up PDX model, primary or metastatic tumor are achieved to translate into immune-deficiency mice. The tumor in immune-deficiency mouse is acquired to translate to other immune-deficiency mouse to generate stable PDX model, which usually is affected by the strain of mouse, translation method and translation location in mouse. PDX models recapitulate the same histology and gene expression as the original patients' carcinoma. PDX models can accurately predict the effectiveness of novel drugs, screen more predictive biomarker for drug resistance and optimize the use of classic drugs in clinic. However, sole source of surgical resection of tumor, long time of construction, high failure rate and hardly used in evaluating immune drugs would be the barriers to be overcome to improve PDX models. The methodological issues, salient features, practical applications, and future directions of PDX models will be illustrated.
Animals
;
Heterografts
;
Humans
;
Mice
;
Neoplasm Transplantation
;
methods
;
Neoplasms
;
physiopathology
;
surgery
;
Translational Medical Research
;
methods
5.Translational Research for Pediatric Lower Urinary Tract Dysfunction.
International Neurourology Journal 2016;20(Suppl 2):S105-S111
This review provides a comprehensive view of translational research aimed at elucidating the pathophysiology of pediatric lower urinary tract dysfunction (LUTD). A web search was conducted according to combinations of keywords, and the significance of each article was defined by the author. The dramatic evolution of the mass analysis method of genomes, transcripts, and proteins has enabled a comprehensive analysis of molecular events underlying diseases, and these methodologies have also been applied to pediatric LUTD. In genetic analyses of syndromes underlying daytime incontinence, urofacial (Ochoa) syndrome may be creating a prototype of a new research approach. Nocturnal enuresis has long been studied genetically, and several candidate loci have been reported. However, the pursuit for enuresis genes has been abandoned partly because genetic association and enuresis phenotype (bladder or renal type) could not be linked. Enuresis associated with diabetes insipidus has provided new insights into the etiology of the diseases. A chronobiological approach may shed new light on this area. Posterior urethral valves and neurogenic bladders have attracted the interest of pediatric urologists to the smooth muscle biology of the bladder. Bladder exstrophy and cloacal anomalies are rare but major anomalies caused by defective urorectal development and have recently been studied from a genetic standpoint. Translational studies for pediatric LUTD may be extended to adult bladder disease, or to application of precision medicine for diseased children.
Adult
;
Biology
;
Bladder Exstrophy
;
Child
;
Diabetes Insipidus
;
Enuresis
;
Genome
;
Genomics
;
Humans
;
Lower Urinary Tract Symptoms
;
Methods
;
Muscle, Smooth
;
Nocturnal Enuresis
;
Pediatrics
;
Phenotype
;
Precision Medicine
;
Translational Medical Research*
;
Urinary Bladder
;
Urinary Bladder Diseases
;
Urinary Incontinence
;
Urinary Tract*
6.Translational Research for Pediatric Lower Urinary Tract Dysfunction.
International Neurourology Journal 2016;20(Suppl 2):S105-S111
This review provides a comprehensive view of translational research aimed at elucidating the pathophysiology of pediatric lower urinary tract dysfunction (LUTD). A web search was conducted according to combinations of keywords, and the significance of each article was defined by the author. The dramatic evolution of the mass analysis method of genomes, transcripts, and proteins has enabled a comprehensive analysis of molecular events underlying diseases, and these methodologies have also been applied to pediatric LUTD. In genetic analyses of syndromes underlying daytime incontinence, urofacial (Ochoa) syndrome may be creating a prototype of a new research approach. Nocturnal enuresis has long been studied genetically, and several candidate loci have been reported. However, the pursuit for enuresis genes has been abandoned partly because genetic association and enuresis phenotype (bladder or renal type) could not be linked. Enuresis associated with diabetes insipidus has provided new insights into the etiology of the diseases. A chronobiological approach may shed new light on this area. Posterior urethral valves and neurogenic bladders have attracted the interest of pediatric urologists to the smooth muscle biology of the bladder. Bladder exstrophy and cloacal anomalies are rare but major anomalies caused by defective urorectal development and have recently been studied from a genetic standpoint. Translational studies for pediatric LUTD may be extended to adult bladder disease, or to application of precision medicine for diseased children.
Adult
;
Biology
;
Bladder Exstrophy
;
Child
;
Diabetes Insipidus
;
Enuresis
;
Genome
;
Genomics
;
Humans
;
Lower Urinary Tract Symptoms
;
Methods
;
Muscle, Smooth
;
Nocturnal Enuresis
;
Pediatrics
;
Phenotype
;
Precision Medicine
;
Translational Medical Research*
;
Urinary Bladder
;
Urinary Bladder Diseases
;
Urinary Incontinence
;
Urinary Tract*
7.Asian Society of Gynecologic Oncology International Workshop 2014.
Jeong Yeol PARK ; Hextan Yuen Sheung NGAN ; Won PARK ; Zeyi CAO ; Xiaohua WU ; Woong JU ; Hyun Hoon CHUNG ; Suk Joon CHANG ; Sang Yoon PARK ; Sang Young RYU ; Jae Hoon KIM ; Chi Heum CHO ; Keun Ho LEE ; Jeong Won LEE ; Suresh KUMARASAMY ; Jae Weon KIM ; Sarikapan WILAILAK ; Byoung Gie KIM ; Dae Yeon KIM ; Ikuo KONISHI ; Jae Kwan LEE ; Kung Liahng WANG ; Joo Hyun NAM
Journal of Gynecologic Oncology 2015;26(1):68-74
The Asian Society of Gynecologic Oncology International Workshop 2014 on gynecologic oncology was held in Asan Medical Center, Seoul, Korea on the 23rd to 24th August 2014. A total of 179 participants from 17 countries participated in the workshop, and the up-to-date findings on the management of gynecologic cancers were presented and discussed. This meeting focused on the new trends in the management of cervical cancer, fertility-sparing management of gynecologic cancers, surgical management of gynecologic cancers, and recent advances in translational research on gynecologic cancers.
Female
;
Fertility Preservation/methods
;
Genital Neoplasms, Female/*therapy
;
Humans
;
Ovarian Neoplasms/therapy
;
Translational Medical Research/methods
;
Uterine Cervical Neoplasms/therapy
8.Research status and translational application of new extraction techniques of traditional Chinese medicine.
Sai-Jun WANG ; Zhen-Feng WU ; Ming YANG ; Ya-Qi WANG ; Fang WANG ; Gang KE ; Ju-Min HUANG
China Journal of Chinese Materia Medica 2014;39(8):1360-1367
Extraction is the critical link during pharmaceutical process of traditional Chinese medicine (TCM), which is directly related to the quality of drugs. So the key to technology upgrading of pharmaceutical equipment in Chinese materia medica enterprise is the development of new extraction techniques, which concerns the modernization of TCM. In this paper, fundamentals, traits, and development status of new extraction technologies were firstly introduced, including ultrasound extraction, microwave extraction, super fluid extraction, semi-bionic extraction method, enzymatic treatment extraction, continuous countercurrent extraction, vacuum extraction. Then information of projects supported by the National Natural Science Foundation of China was analyzed in order to recognize the assistance and research results of new extraction techniques. The patents authorized by the State Intellectual Property Office were also summarized for the purpose of understanding the achievement transformation. The information about extraction equipments was collected and screened to acquire the characteristics and market situation. The results showed that there are still problems about new extraction technologies, such as weak basic study, hard transformation of achievements, and the disconnection between research study and practical application. It is necessary to discuss the approaches and methods for accelerating the transformation of fundamental research, which will provide references for the long-term development of new extraction techniques of TCM.
Chemistry, Pharmaceutical
;
economics
;
methods
;
trends
;
China
;
Drugs, Chinese Herbal
;
analysis
;
economics
;
isolation & purification
;
Medicine, Chinese Traditional
;
economics
;
trends
;
Plants, Medicinal
;
chemistry
;
Translational Medical Research
;
trends
9.Strategy and core technologies for the secondary development of Chinese patent medicine.
Bo-Li ZHAGN ; Xiao-Hui FAN ; Yang LIU ; Hai-Bin QU ; Jun-Hua ZHANG ; Yi-Yu CHEGN
China Journal of Chinese Materia Medica 2013;38(22):3797-3800
Secondary development of Chinese Patent Medicine (CPM) is an effective and innovation-driven way for the leaping development of Chinese medicine industry with less investment and faster return. Aim to improving the efficacy, safety and batch-to-batch consistency of CPMs, the theory and methodology for the secondary development of CPMs, mode for cultivating superior CPM, approaches to reforming the pharmaceutical technology and the corresponding core technologies were proposed in this paper, which is summarized as 'One objective, Three analyses, Five definitudes and Seven improvements'.
Drugs, Chinese Herbal
;
chemistry
;
economics
;
Patents as Topic
;
Technology, Pharmaceutical
;
economics
;
legislation & jurisprudence
;
methods
;
Translational Medical Research
;
economics
;
legislation & jurisprudence
;
methods
10.Translational epidemiology.
Yi LIU ; Hong-zhuan TAN ; Di WU
Chinese Journal of Epidemiology 2013;34(9):940-942

Result Analysis
Print
Save
E-mail